FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
The FDA has granted accelerated approval to Bristol Myers Squibb's Zenbexus, introducing a novel CELMoD drug class for multiple myeloma treatment.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
The FDA granted accelerated approval to Bristol Myers Squibb's Zenbexus for patients with multiple myeloma as early as first relapse. The drug was approved for use in combination with dexamethasone and daratumumab and hyaluronidase-fihj, marking the debut of the CELMoD drug class.
Epilogue added 93d ago, after coverage quieted.
The brief
Food and Drug Administration has granted accelerated approval to Bristol Myers Squibb for its first CELMoD therapy, known as Zenbexus. This new treatment is indicated for patients suffering from multiple myeloma, specifically those experiencing their first relapse. According to an official announcement from Bristol Myers Squibb, Zenbexus is intended for use in a specific combination therapy alongside Dexamethasone and Daratumumab and Hyaluronidase-fihj, referred to as ZDd. This regulatory milestone marks the official debut of the CELMoD drug class, a novel category of therapy for blood cancer patients. Coverage of the approval has been widespread across medical and financial news outlets. Reuters reported on the FDA's approval of the blood cancer treatment, while STAT highlighted that the decision marks the debut of a novel drug class.
Fierce Pharma specifically noted that Bristol Myers Squibb has secured the first approval for its CELMoD franchise via the Zenbexus nod. Additionally, OncLive integrated the update into its weekly news quiz regarding myeloma, lung cancer, and polycythemia vera, emphasizing the clinical relevance of the approval within the oncology community. This development arrives at a critical juncture for Bristol Myers Squibb's business portfolio. According to BioSpace, the company welcomes this new multiple myeloma drug at a time when its current portfolio is being battered by generics. The emergence of generic alternatives for existing products has created a need for new, proprietary therapies to sustain revenue. Yahoo Finance has raised questions regarding the company's stock price, questioning whether the market has already fully priced in the impact of this FDA win for the ticker symbol BMY.
Future developments will likely center on the clinical performance of the Zenbexus combination therapy in patients with multiple myeloma. Since the FDA granted accelerated approval, the company will need to follow the regulatory requirements associated with that designation. Stakeholders and analysts will be monitoring whether this first CELMoD therapy can successfully offset the losses incurred from generic competition. The industry will also watch for the potential expansion of the CELMoD franchise beyond this initial approval as Bristol Myers Squibb integrates the new drug into its oncology lineup.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 93d ago.
Quick answers
What is Zenbexus?
Zenbexus is the first CELMoD therapy from Bristol Myers Squibb, recently granted accelerated FDA approval for treating multiple myeloma.
How is Zenbexus administered?
It is used in combination with Dexamethasone and Daratumumab and Hyaluronidase-fihj (ZDd) for patients as early as their first relapse.
Why is this approval significant for Bristol Myers Squibb?
It introduces a novel drug class and provides a new product as the company's current portfolio faces pressure from generics.
Coverage (7)
- BMS welcomes new multiple myeloma drug as generics batter current portfolio BioSpace · 95d ago
- OncLive Weekly News Quiz (8/14/2026): Did You Catch This Week's Myeloma, Lung Cancer, and Polycythemia Vera Updates? OncLive · 95d ago
- Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Stock Fully Priced? Yahoo Finance · 95d ago
- U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse Bristol Myers Squibb · 95d ago
- BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod Fierce Pharma · 95d ago
- US FDA approves Bristol Myers' blood cancer treatment Reuters · 95d ago
- FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class STAT · 95d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.